News articles about Cyclacel Pharmaceuticals (NASDAQ:CYCC) have trended somewhat positive on Wednesday, according to Accern. The research group identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cyclacel Pharmaceuticals earned a news sentiment score of 0.17 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 46.8384434611365 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Here are some of the news stories that may have impacted Accern’s analysis:

Shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) opened at $2.00 on Wednesday. Cyclacel Pharmaceuticals has a fifty-two week low of $1.50 and a fifty-two week high of $10.90.

ILLEGAL ACTIVITY WARNING: This article was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.thecerbatgem.com/2017/12/06/cyclacel-pharmaceuticals-cycc-earns-news-sentiment-score-of-0-17.html.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors.

Insider Buying and Selling by Quarter for Cyclacel Pharmaceuticals (NASDAQ:CYCC)

Receive News & Stock Ratings for Cyclacel Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.